The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4‐related systemic disease
Abstract
Objective: Patients with IgG4‐related systemic disease (IgG4‐RSD) frequently show an incomplete response to treatment with glucocorticoids and traditional disease‐modifying antirheumatic drugs (DMARDs). B lymphocyte depletion is a therapeutic strategy known to be effective for pemphigus vulgaris, an autoimmune condition mediated by IgG4 autoantibodies. This study was performed to assess the clinical and serologic responses to B lymphocyte depletion therapy with rituximab in patients with IgG4‐RSD. Methods: Four patients with IgG4‐RSD were treated with 2 intravenous doses (1 gram each) of rituximab. Clinical improvement was assessed by monitoring the tapering/discontinuation of prednisone and DMARDs, and by measuring the serum concentrations of B lymphocytes, immunoglobulins, and IgG subclasses before and after therapy. Results: Clinical features of IgG4‐RSD in these 4 patients included autoimmune pancreatitis, sclerosing cholangitis, lymphoplasmacytic aortitis, salivary gland involvement, orbital pseudotumor, and lacrimal gland enlargement. The 3 patients with elevated serum IgG and IgG4 levels at baseline had a mean IgG concentration of 2,003 mg/dl (normal range 600–1,500 mg/dl) and a mean IgG4 concentration of 2,160 mg/dl (normal range 8–140 mg/dl). Among these patients, the serum IgG4 concentrations declined by a mean of 65% within 2 months of rituximab administration. All 4 patients demonstrated striking clinical improvement within 1 month of the initiation of rituximab therapy, and tapering or discontinuation of their treatment with prednisone and DMARDs was achieved in all 4 patients. A decrease in IgG concentration was observed for the IgG4 subclass only. Conclusion: Treatment with rituximab led to prompt clinical and serologic improvement in these patients with refractory IgG4‐RSD, and is a viable treatment option for this condition. The decline in serum IgG4 concentrations was substantially steeper than that of the autoantibody concentrations in immune‐mediated conditions in which rituximab is effective, such as in rheumatoid arthritis. In addition, the reduction in IgG‐subclass levels appeared to be specific for IgG4. The swift improvement of IgG4‐RSD suggests that rituximab achieves its effects in IgG4‐RSD by depleting the pool of B lymphocytes that replenish short‐lived IgG4‐secreting plasma cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High Serum IgG4 Concentrations in Patients with Sclerosing Pancreatitis
Hamano, H., Kawa, S., Horiuchi, A., Unno, H., Furuya, N., Akamatsu, T., Fukushima, M., Nikaido, T., Nakayama, K., Usuda, N., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441005 · Cited by 2,705
A new clinicopathological entity of IgG4-related autoimmune disease
Kamisawa, T., Funata, N., Hayashi, Y., Eishi, Y., Koike, M., Tsuruta, K., Okamoto, A., Egawa, N., & Nakajima, H. (2003) · Journal of Gastroenterology · doi:10.1007/s00535-003-1175-y · Cited by 1,457
Yoshida, K., Toki, F., Takeuchi, T., Watanabe, S.-I., Shiratori, K., & Hayashi, N. (1995) · Digestive Diseases and Sciences · doi:10.1007/bf02285209 · Cited by 1,430
Zen, Y., Fujii, T., Harada, K., Kawano, M., Yamada, K., Takahira, M., & Nakanuma, Y. (2007) · Hepatology · doi:10.1002/hep.21697 · Cited by 652
IgE Versus IgG4 Production Can Be Differentially Regulated by IL-10
Jeannin, P., Lecoanet, S., Delneste, Y., Gauchat, J.-F., & Bonnefoy, J.-Y. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.7.3555 · Cited by 581
Grass Pollen Immunotherapy Induces Mucosal and Peripheral IL-10 Responses and Blocking IgG Activity
Nouri-Aria, K. T., Wachholz, P. A., Francis, J. N., Jacobson, M. R., Walker, S. M., Wilcock, L. K., Staple, S. Q., Aalberse, R. C., Till, S. J., & Durham, S. R. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.3252 · Cited by 564
IgG4-related sclerosing disease
Kamisawa, T., & Okamoto, A. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.3948 · Cited by 458
Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus
Anolik, J. H., Barnard, J., Cappione, A., Pugh‐Bernard, A. E., Felgar, R. E., Looney, R. J., & Sanz, I. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20592 · Cited by 456
Keystone, E., Fleischmann, R., Emery, P., Furst, D. E., van Vollenhoven, R., Bathon, J., Dougados, M., Baldassare, A., Ferraccioli, G., Chubick, A., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.23059 · Cited by 337
Autoimmune Pancreatitis: A Systemic Immune Complex Mediated Disease
Deshpande, V., Chicano, S., Finkelberg, D., Selig, M. K., Mino-Kenudson, M., Brugge, W. R., Colvin, R. B., & Lauwers, G. Y. (2006) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213331.09864.2c · Cited by 315
Self-citation
Cited by
Stone, J. H., Zen, Y., & Deshpande, V. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1104650 · Cited by 2,616
Self-citationConsensus statement on the pathology of IgG4-related disease
Deshpande, V., Zen, Y., Chan, J. K., Yi, E. E., Sato, Y., Yoshino, T., Klöppel, G., Heathcote, J. G., Khosroshahi, A., Ferry, J. A., et al. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.72 · Cited by 2,596
Self-citationKamisawa, T., Zen, Y., Pillai, S., & Stone, J. H. (2015) · The Lancet · doi:10.1016/s0140-6736(14)60720-0 · Cited by 1,212
Self-citationInternational Consensus Guidance Statement on the Management and Treatment of IgG4‐Related Disease
Khosroshahi, A., Wallace, Z. S., Crowe, J. L., Akamizu, T., Azumi, A., Carruthers, M. N., Chari, S. T., Della‐Torre, E., Frulloni, L., Goto, H., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39132 · Cited by 1,064
Self-citationStone, J. H., Khosroshahi, A., Deshpande, V., Chan, J. K. C., Heathcote, J. G., Aalberse, R., Azumi, A., Bloch, D. B., Brugge, W. R., Carruthers, M. N., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34593 · Cited by 730
Self-citationRituximab for IgG4-related disease: a prospective, open-label trial
Carruthers, M. N., Topazian, M. D., Khosroshahi, A., Witzig, T. E., Wallace, Z. S., Hart, P. A., Deshpande, V., Smyrk, T. C., Chari, S., & Stone, J. H. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206605 · Cited by 726
Self-citationA novel clinical entity, IgG4-related disease (IgG4RD): general concept and details
Umehara, H., Okazaki, K., Masaki, Y., Kawano, M., Yamamoto, M., Saeki, T., Matsui, S., Sumida, T., Mimori, T., Tanaka, Y., et al. (2012) · Modern Rheumatology · doi:10.3109/s10165-011-0508-6 · Cited by 680
IgG4‐Related Disease: Clinical and Laboratory Features in One Hundred Twenty‐Five Patients
Wallace, Z. S., Deshpande, V., Mattoo, H., Mahajan, V. S., Kulikova, M., Pillai, S., & Stone, J. H. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39205 · Cited by 666
Self-citationRituximab for the Treatment of IgG4-Related Disease: Lessons From 10 Consecutive Patients
Khosroshahi, A., Carruthers, M. N., Deshpande, V., Unizony, S., Bloch, D. B., & Stone, J. H. (2012) · Medicine · doi:10.1097/md.0b013e3182431ef6 · Cited by 489
Self-citationIgG4-related Sclerosing Disease: A Critical Appraisal of an Evolving Clinicopathologic Entity
Cheuk, W., & Chan, J. K. C. (2010) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181ee63ce · Cited by 452
The Neonatal Fc Receptor (FcRn): A Misnomer?
Pyzik, M., Sand, K. M. K., Hubbard, J. J., Andersen, J. T., Sandlie, I., & Blumberg, R. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01540 · Cited by 429
IgG4-related disease: an update on pathophysiology and implications for clinical care
Perugino, C. A., & Stone, J. H. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0500-7 · Cited by 421
Self-citationClonal expansion of CD4+ cytotoxic T lymphocytes in patients with IgG4-related disease
Mattoo, H., Mahajan, V. S., Maehara, T., Deshpande, V., Della-Torre, E., Wallace, Z. S., Kulikova, M., Drijvers, J. M., Daccache, J., Carruthers, M. N., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.12.1330 · Cited by 406
Self-citationMattoo, H., Mahajan, V. S., Della-Torre, E., Sekigami, Y., Carruthers, M., Wallace, Z. S., Deshpande, V., Stone, J. H., & Pillai, S. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.03.034 · Cited by 386
Self-citationMahajan, V. S., Mattoo, H., Deshpande, V., Pillai, S. S., & Stone, J. H. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104708 · Cited by 366
Self-citationAdvances in the diagnosis and management of IgG4 related disease
Lanzillotta, M., Mancuso, G., & Della-Torre, E. (2020) · BMJ · doi:10.1136/bmj.m1067 · Cited by 360
The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes
Marx, A., Pfister, F., Schalke, B., Saruhan-Direskeneli, G., Melms, A., & Ströbel, P. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.03.007 · Cited by 351
A clinical overview of IgG4-related systemic disease
Khosroshahi, A., & Stone, J. H. (2011) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3283418057 · Cited by 328
Self-citationWhat is IgG4? A review of the biology of a unique immunoglobulin subtype
Nirula, A., Glaser, S. M., Kalled, S. L., & Taylora, F. R. (2011) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3283412fd4 · Cited by 309
MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4
Huijbers, M. G., Zhang, W., Klooster, R., Niks, E. H., Friese, M. B., Straasheijm, K. R., Thijssen, P. E., Vrolijk, H., Plomp, J. J., Vogels, P., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313944110 · Cited by 297
Chapman, M. H., Thorburn, D., Hirschfield, G. M., Webster, G. G. J., Rushbrook, S. M., Alexander, G., Collier, J., Dyson, J. K., Jones, D. E., Patanwala, I., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-317993 · Cited by 284
The Unique Properties of IgG4 and Its Roles in Health and Disease
Rispens, T., & Huijbers, M. G. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00871-z · Cited by 282
Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders
Kaegi, C., Wuest, B., Schreiner, J., Steiner, U. C., Vultaggio, A., Matucci, A., Crowley, C., & Boyman, O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01990 · Cited by 260
Ebbo, M., Grados, A., Samson, M., Groh, M., Loundou, A., Rigolet, A., Terrier, B., Guillaud, C., Carra-Dallière, C., Renou, F., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0183844 · Cited by 253
European Guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendations
Löhr, J., Beuers, U., Vujasinovic, M., Alvaro, D., Frøkjær, J. B., Buttgereit, F., Capurso, G., Culver, E. L., de‐Madaria, E., Della‐Torre, E., et al. (2020) · United European Gastroenterology Journal · doi:10.1177/2050640620934911 · Cited by 252
The Role of B Cells and B Cell Therapies in Immune-Mediated Liver Diseases
Cargill, T., & Culver, E. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661196 · Cited by 46
Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin
Ma, G., Crowley, A. R., Heyndrickx, L., Rogiers, I., Parthoens, E., Van Santbergen, J., Ober, R. J., Bobkov, V., de Haard, H., Ulrichts, P., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.176166 · Cited by 28
Metadata
- Authors
- Khosroshahi, A., Bloch, D. B., Deshpande, V., & Stone, J. H.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2010-05-28
- Volume
- 62
- Issue
- 6
- Pages
- 1755-1762
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2046297453
- Cited by
- 522
- References
- 21
- FWCI
- 27.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.